HIV Therapeutics

Pharmaceutical company reports positive data on HIV drug to FDA

Published in AIDS Weekly, November 24th, 2003

Samaritan Pharmaceuticals Inc. (SPHC) and Samaritan Research Labs, Georgetown University, has submitted its phase II clinical study report, with positive data demonstrating statistical significance for viral load and quality of life to the U.S. Food and Drug Administration (FDA).

Based on the encouraging results, Samaritan is in the process of developing a phase III clinical study regimen designed to attack the virus in new ways.

Dr. Janet Greeson, chief executive officer of Samaritan Pharmaceuticals, stated, "While AIDS related deaths have declined, the number of people living with HIV still continues to grow. We are attempting to design a phase III...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-11-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry